clinical trial · NCT00246922
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
AstraZeneca·phase3·completed·n = 150
Bronchial AsthmaRoflumilast
brief summary
The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with asthma, who completed the 24-week evaluation of study APTA-2217-05. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is the extension of the 24-week study APTA-2217-05 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.
started
Dec 1, 2004
primary completion
Jan 1, 2007
completion
Oct 1, 2007
last updated
Feb 18, 2026
official title
A Long-term Study of APTA-2217 in Adult Patients With Bronchial Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol